UpdatesGeneral Updates
SPARC clarified its valuation report following an NSE query, explaining why income-based valuation (DCF) is unsuitable.
Sun Pharma Advanced Research Company LimitedSPARC · Filed with the exchange
This is due to its R&D business, consistent losses, and lack of predictable revenue streams, making future projections difficult.
No comments yet. Be the first.